Abstract:BackgroundNumerous preclinical studies have revealed a critical role of Cysteine rich 61 (Cyr61) in the pathogenesis of rheumatoid arthritis (RA). However, little is known about the potential value of circulation Cyr61 in clinical RA patients.ObjectivesTo compare serum Cyr61 level in patients with RA and healthy controls, and to characterize the potential association between Cyr61 and RA disease activity.MethodsIn training cohort, serum samples were obtained from 177 patients with definite RA and 50 age- and gender- matched healthy controls. Medical records were collected and serum Cyr61 concentration was detected by enzyme-linked immunosorbent assay. Correlations between Cyr61 levels with clinical disease activity were analyzed. Furthermore, a validation cohort consisting of 77 active RA patients who received uniform biologic therapy for 12 weeks was set up (ClinicalTrials.gov identifier: NCT02320630). Paired serum samples were collected at baseline and after 12-week treatment for each individual and prepared for detection of Cyr61. Comparisons between groups were made using Mann-Whitney U test or Wilcoxon matched-pairs signed rank test, as appropriate.ResultsSignificant elevation of serum Cyr61 concentration was found in RA patients, demonstrating excellent diagnostic ability to discriminate RA with healthy controls (area under the curve (AUC) = 0.98, P < 0.001). In training cohort, Cyr61 level in active RA patients was significantly lower than that in inactive RA, and it was inversely with measures of clinical disease activity in statistic. Findings were further confirmed in our validation cohort. Active RA patients who had a reduction in disease activity showed a significantly increase of Cyr61 level after effective treatment (in terms of achieving ACR20/50/70 improvement criteria). RA patients who did not achieve ACR response showed no significant difference of Cyr61 level before and after treatment. Multivariate logistic regression analysis revealed that increase of Cyr61 level as well as younger age were independent indicators for achieving ACR20 response.ConclusionSerum Cyr61 levels were remarkably increased in RA patients compared with healthy control. More intriguingly, the level of Cyr61 was inversely associated with RA disease activity and increased after effective treatment.References[1] Zhang Q, Wu J, Cao Q, Xiao L, Wang L, He D, et al. A critical role of Cyr61 in interleukin-17-dependent proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis & Rheumatism. 2009;60(12):3602-12. [2] Chen CY, Su CM, Hsu CJ, Huang CC, Wang SW, Liu SC, et al. CCN1 Promotes VEGF Production in Osteoblasts and Induces Endothelial Progenitor Cell Angiogenesis by Inhibiting miR-126 Expression in Rheumatoid Arthritis. J BONE MINER RES. 2017 2017-01-01;32(1):34-45. [3] Barranco C. CCN1, a novel RA target? NAT REV RHEUMATOL. 2016 2016-08-19;12(10):561.Conflict of interestThe authors declare that they have no competing interests.Disclosure of InterestsNone declared

Higher Serum CCN3 is Associated with Disease Activity and Inflammatory Markers in Rheumatoid Arthritis

[Serum Levels of Several Chemokines in Patients with Rheumatoid Arthritis].

Serum Levels of IL-1, TNF-α, IL-2, IFN-γ and Neopterin in Patients with Rheumatoid Arthritis

Extensive study of CCN4, VCAM-1, MMP-3, and GM-CSF as reliable markers for disease activity in rheumatoid arthritis

Serum Levels of 14‑3‑3η Are Associated with Increased Disease Risk, Activity and Duration of Rheumatoid Arthritis in Chinese Patients

Expression of RNATES,MCP-1 in serum and synovial fluid in patients with rheumatoid arthritis and its clinical significance

CCN3/NOV serum levels in coronary artery disease (CAD) patients and its correlation with TNF-α and IL-6

14-3-3Η Protein in Rheumatoid Arthritis: Promising Diagnostic Marker and Independent Risk Factor for Osteoporosis.

Clinical Significance of Serum C-C Chemokine Ligand 19 Levels in Patients with Rheu-Matoid Arthritis

AB0243 CYSTEINE RICH 61 (CYR61): A POTENTIAL BIOMARKER ASSOCIATED WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS

Decoy Receptor3 in Rheumatoid Arthritis Patient and Its Clinical Relevance

Expression of calreticulin and its relationship with autoantibodies and inflammatory cytokines in early rheumatoid arthritis

CCL3 Participates in the Development of Rheumatoid Arthritis by Activating AKT

Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis.

Value of Serum Collagen Triple Helix Repeat Containing-1(Cthrc1) and 14-3-3η Protein Compared to Anti-Ccp Antibodies and Anti-Mcv Antibodies in the Diagnosis of Rheumatoid Arthritis

Serum CHI3L1 as a biomarker of interstitial lung disease in rheumatoid arthritis

The diagnostic significance of anti-cyclic citrullinated peptide 3.1 IgG/IgA antibody in patients with rheumatoid arthritis

The Emerging Roles of CCN3 Protein in Immune-Related Diseases

Potential Significance of Changes in Serum Levels of IL-17, TNF-α and DKK-1 in the Progression of the Rheumatoid Arthritis

Urinary Mrna Expression of CCN2/CCN3 As a Noninvasive Marker for Monitoring Glomerular Structure Changes in Nondiabetic Chronic Kidney Disease

Tumor necrosis factor like ligand-1A in rheumatoid arthritis patient and its clinical relevance analysis